Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179927 | 0.86 | GRIN2D (0.37) | FAAHKDM4E | |
| SCHEMBL4182378 | 0.82 | CYP2C9 (0.42) | KDM4E | |
| SCHEMBL4184892 | 0.82 | GPR119 (0.45) | GPR119FAAHKDM4EPKMTP53 | |
| SCHEMBL13950927 | 0.81 | PARP1 (0.48) | GPR119 | |
| SCHEMBL4192189 | 0.78 | KDM4E (0.41) | GPR119KDM4EMAPTTHRB | |
| SCHEMBL4192185 | 0.78 | KDM4E (0.41) | GPR119KDM4EMAPTTHRB | |
| SCHEMBL13282013 | 0.74 | MAOB (0.53) | GPR119FAAHKDM4EPKMTP53 | |
| SCHEMBL20015389 | 0.74 | GPR119 (0.60) | GPR119FAAHKDM4EPKMTP53 | |
| SCHEMBL30824890 | 0.74 | GPR119 (0.58) | GPR119FAAHKDM4EPKMTP53 | |
| SCHEMBL14783164 | 0.73 | FAAH (0.51) | GPR119FAAHKDM4EMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | HTR5A, CRH, CYP17A1 | GPR119 100/4885FAAH 154/4885KDM4E 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.